Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by Neoadjuvant Chemotherapy With Cisplatine

Research Leaders

5 sponsors active, led by Institut Claudius Regaud

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

Trial Status

Recruiting1
Unknown1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT07821879Recruiting

Routine Shallow-coverage Whole Genome Sequencing Testing of Liquid-based Cervical Smears for the Early Diagnosis of Ovarian Cancer

NCT06477718CompletedPrimary

Genomic Signatures for Patients With Initially Unresectable Colorectal Liver Metastases

NCT06294054Unknown

Bladder Cancer and Neoadjuvant Chemotherapy Efficiency Before Cystectomy

Showing all 3 trials

Research Network

Common Treatments

  • Neoadjuvant Chemotherapy With Cisplatine1

Active Sponsors

  • Institut Claudius Regaud1
  • University Hospital, Rouen1
  • Institut Universitaire du Cancer de Toulouse1
  • Institut Curie1
  • The First Affiliated Hospital with Nanjing Medical University1

Top Investigators

Related Conditions

  • High Grade Serous Ovarian Cancer1
  • Prognostic Cancer Model1
  • Cervical Cancer Screening1
  • Bladder Cancer1
  • Whole Genome Sequencing1

Activity Timeline